Abstract: Objective To study the influence of Terlipressin, Octreotide or their combination on hepatic venous pressure gradient (HVPG) and blood flow velocity (BFV) in patients with hepatic cirrhosis (LC). Methods The clinical data of 66 patients with hepatic cirrhosis and varicose veins from May 2014 to April 2016 were retrospectively analyzed. According to the treatment methods, they were divided into Terlipressin group (T group), Octreotide group (O group) and united group (L group). Before and after treatment, hepatic vein wedge pressure (WHVP), hepatic vein free pressure (FHVP), HVPG and portal vein BFV were measured. Results There were significant differences in HVPG levels at different time (P < 0.05). There were differences in WHVP and HVPG between the L group or the O group and the T group (P < 0.05). There was significant difference in HVPG between the L group and the O group (P < 0.05). There were differences in portal vein BFV after treatment among the three groups (P < 0.05). There were differences in the variation trends of FHVP, HVPG and portal vein BFV between the L group and the O group or the T group (P < 0.05). Conclusions Terlipressin and Octreotide can reduce HVPG and increase BFV. The effects of the combination of the two drugs are better than those of single medication.